Vertex Pharmaceuticals (VRTX) financials
Vertex Pharmaceuticals revenue and earnings by year
Vertex Pharmaceuticals's revenue was $12.0 billion in the fiscal year to December 31, 2025, up 8.9% from the year before. Net income was $3.95 billion, 32.9% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 24.2% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.0 | 11.0 | 9.9 | 8.9 | 7.6 | 6.2 | 4.2 | 3.0 | 2.5 | 1.7 |
| Revenue growth | 8.9% | 11.7% | 10.5% | 17.9% | 22.1% | 49.1% | 36.6% | 22.5% | 46.2% | — |
| Gross profit | 10.4 | 9.5 | 8.6 | 7.9 | 6.7 | 5.5 | 3.6 | 2.6 | 2.2 | 1.5 |
| Gross margin | 86.2% | 86.1% | 87.2% | 87.9% | 88.1% | 88.1% | 86.8% | 86.6% | 88.9% | 87.6% |
| Operating income | 4.2 | -0.2 | 3.8 | 4.2 | 2.8 | 2.9 | 1.2 | 0.6 | 0.1 | 0.0 |
| Operating margin | 34.8% | -2.1% | 38.3% | 47.6% | 36.7% | 46.2% | 28.9% | 20.8% | 5.0% | 0.6% |
| Net income | 4.0 | -0.5 | 3.6 | 3.3 | 2.3 | 2.7 | 1.2 | 2.1 | 0.3 | -0.1 |
| Net margin | 32.9% | -4.9% | 36.7% | 37.2% | 30.9% | 43.7% | 28.3% | 68.8% | 10.6% | -6.6% |
| Diluted EPS | $15.32 | -$2.08 | $13.89 | $12.82 | $9.01 | $10.30 | $4.51 | $8.08 | $1.04 | -$0.46 |
| Free cash flow | 3.2 | -0.8 | 3.3 | 3.9 | 2.4 | 3.0 | 1.5 | 1.2 | 0.7 | 0.2 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open VRTX in Markets.
How Vertex Pharmaceuticals makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| TRIKAFTAKAFTRIO | $2.50B | 74.9% |
| ALYFTREK | $574M | 17.2% |
| Manufactured Product Other | $137M | 4.1% |
| CASGEVY | $76.4M | 2.3% |
| JOURNAVX | $49.6M | 1.5% |
See also: VRTX valuation and P/E history · VRTX returns
No forecast, no recommendation. This page describes Vertex Pharmaceuticals from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.